Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

Novartis Announces $23 Billion U.S. Expansion with New Plants and R&D Hub

The pharmaceutical giant plans to build six manufacturing plants and a San Diego research facility, creating over 4,000 jobs as part of a U.S.-first strategy.

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Image
Vials of medicine on the Wegovy injection pen production line at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024. Novo is cutting back on recruiting in Denmark after reaching the limits of its home country's labor market in the rush to add capacity for blockbuster drugs Ozempic and Wegovy. Photographer: Charlotte de la Fuente/Bloomberg via Getty Images

Overview

  • Novartis unveiled a $23 billion investment plan to build and expand 10 facilities across the United States over the next five years.
  • The expansion includes six new manufacturing plants and a research and development site in San Diego, California.
  • The project is expected to generate over 4,000 jobs, including 1,000 skilled positions and 3,000 construction and support roles.
  • The move aligns with Novartis' U.S.-first strategy to produce drugs domestically and strengthen its position in the U.S. pharmaceuticals market.
  • While the decision considers proposed pharmaceutical import tariffs by President Trump, Novartis emphasized that tariffs are not the primary driving factor.